rs25487, XRCC1

N. diseases: 205
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Prostate carcinoma
CUI: C0600139
Disease: Prostate carcinoma
0.100 GeneticVariation BEFREE Based on these results, the XRCC1-Arg399Gln polymorphism might be a risk factor for PCa and it could be considered as a prognostic and predictive biomarker for susceptible men. 30160806 2018
Prostate carcinoma
CUI: C0600139
Disease: Prostate carcinoma
0.100 GeneticVariation BEFREE In summary, we suggest that XRCC1 Arg399Gln might be significantly associated with development of Pca. 25262700 2015
Prostate carcinoma
CUI: C0600139
Disease: Prostate carcinoma
0.100 GeneticVariation BEFREE Overall, the results of this meta-analysis show that the XRCC1-Arg399Gln polymorphism may be associated with an increased risk for prostate cancer under the homozygote model and the recessive model. 25927275 2015
Prostate carcinoma
CUI: C0600139
Disease: Prostate carcinoma
0.100 GeneticVariation BEFREE We examined the association between PC risk with nonsynonymous SNPs (nsSNPs) in 5 genes involved in 3 DNA-repair pathways: (1) base excision repair (BER): hOGG1 C1245G (Ser326Cys) and XRCC1 G28152A (Arg399Gln); (2) nucleotide excision repair (NER): XPD G23591A (Asp312Asn); (3) homologous recombination repair: RAD51 G135C (in 5' untranslated region) and XRCC3 C18067T (Thr241Met). 19914098 2012
Prostate carcinoma
CUI: C0600139
Disease: Prostate carcinoma
0.100 GeneticVariation BEFREE In this meta-analysis, we found that both Arg399Gln and Arg194Trp polymorphisms were not related to overall PCa risk. 21647176 2011
Prostate carcinoma
CUI: C0600139
Disease: Prostate carcinoma
0.100 GeneticVariation BEFREE However, our results also suggested that XRCC1 Arg399Gln polymorphism was not significantly associated with pr</span>ostate cancer in white men. 19428062 2009
Prostate carcinoma
CUI: C0600139
Disease: Prostate carcinoma
0.100 GeneticVariation BEFREE Haplotype analysis of XRCC1 Arg194Trp (C/T) and Arg399Gln (G/A) revealed that the frequency of the T-A haplotype was significantly higher in PC patients. 17196815 2007
Prostate carcinoma
CUI: C0600139
Disease: Prostate carcinoma
0.100 GeneticVariation BEFREE Among the three polymorphisms, we found that the XRCC1 Arg399Gln variant allele was associated with increased PCa risk (adjusted odd ratio [OR]: 1.67, 95% confident interval [CI]: 1.11-2.51), but the XRCC1 Arg194Trp variant allele had a 38% reduction in risk of PCa (adjusted OR: 0.62, 95% CI: 0.41-0.93). 17486273 2007
Prostate carcinoma
CUI: C0600139
Disease: Prostate carcinoma
0.100 GeneticVariation BEFREE We found that the XRCC1-Arg399Gln AA and the MGMT-Leu84Phe CT+TT genotypes were associated with an increased risk of prostate cancer [odds ratio (OR), 2.18; 95% confidence interval (CI), 0.99-4.81 and OR, 1.99; 95% CI, 1.19-3.34, respectively]. 16030105 2005
Prostate carcinoma
CUI: C0600139
Disease: Prostate carcinoma
0.100 GeneticVariation BEFREE To determine whether the XRCC1 (codon Arg399Gln) and XPD (codon Asp312Asn and codon Lys751Gln) polymorphisms are associated with prostate cancer susceptibility, we genotyped these polymorphisms in a primarily Caucasian sample of 506 sibships (n = 1,117) ascertained through a brother with prostate cancer. 14744728 2004